Cancer is one of the leading causes of death worldwide. Several treatments are available for
cancer treatment, but many treatment methods are ineffective against multidrug-resistant …

Abstract P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX)
resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2 …

Cancer cells frequently display intrinsic or acquired resistance to chemically diverse
anticancer drugs, limiting therapeutic success. Among the main mechanisms of this …

Cancer is one of the primary causes of death worldwide, and its incidence continues to
increase yearly. Despite significant advances in research, the search for effective and …

One of the primary causes of attenuated or loss of efficacy of cancer chemotherapy is the
emergence of multidrug resistance (MDR). Numerous studies have been published …

Cancers have the ability to develop resistance to traditional therapies, and the increasing
prevalence of these drug resistant cancers necessitates further research and treatment …

Resistance to chemotherapy and molecularly targeted therapies is a major problem facing
current cancer research. The mechanisms of resistance to'classical'cytotoxic …

Multidrug resistance (MDR) is a major cause of failure in cancer chemotherapy. P-
glycoprotein (P-gp), a promiscuous drug efflux pump, has been extensively studied for its …

Background Cisplatin-based chemotherapy is frequently used to treat advanced gastric
cancer (GC). However, the resistance often occurs with the mechanisms being not well …

Chemoresistant metastatic relapse of minimal residual disease plays a significant role for
poor prognosis of cancer. Growing evidence supports a critical role of cancer stem cell …